Grail rises after announcing $325 million raise from Hims, others
Grail, a cancer detection biotech, rose more than 20% after it announced that it raised $325 million from a slate of investors including Hims & Hers.
Grail sells a blood test that detects cancerous tumors early on. The company also announced encouraging trial results for its flagship test, Galleri, on Friday.
Grail sold 4,639,543 shares at $70.05, a discount from the $78 closing price on Friday, to a group of more than six investors. Hims did not immediately respond to questions from Sherwood News, including how much of the $325 million fundraise it contributed. Grail announced last week that it received a $110 million investment from Samsung.
Grail reported $67.4 million in revenue in the first half of this year, up from $58.6 million in the same period in 2024. Galleri is available commercially but is pending approval from the Food and Drug Administration, which could position it to be covered by major insurers.
Today we announce a strategic investment in $GRAL — the most advanced Multi-Cancer Early Detection (MCED) test on the market.
— andrewdudum (@AndrewDudum) October 20, 2025
When I was 12, my father was diagnosed with stage 4 colon cancer. He was 38 at the time, about the same age as I am today.
Since hearing about early…
Today we announce a strategic investment in $GRAL — the most advanced Multi-Cancer Early Detection (MCED) test on the market.
— andrewdudum (@AndrewDudum) October 20, 2025
When I was 12, my father was diagnosed with stage 4 colon cancer. He was 38 at the time, about the same age as I am today.
Since hearing about early…